Stocktoria
CRESCENT BIOPHARMA, INC. CBIO
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2014-01-10
CRESCENT BIOPHARMA, INC. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.8M | — | $10,000 | $75,000 | $1.2M | $10.2M | — | — | — | $18,500 |
| R&D expense | $138.1M | $14.3M | $20.1M | $28.4M | $47.5M | $44.9M | $47.0M | $40.1M | $24.1M | $23.3M |
| Operating income | -$152.6M | -$40.0M | -$39.3M | -$47.4M | -$63.4M | -$51.5M | -$61.4M | -$51.5M | -$33.9M | -$31.9M |
| Income tax | $2.0M | — | — | — | — | — | — | — | — | — |
| Net income | -$153.9M | -$37.9M | -$36.9M | -$46.7M | -$63.4M | -$51.0M | -$57.9M | -$48.3M | -$33.3M | -$31.8M |
| EPS (diluted) | — | $-0.59 | $-0.58 | $-0.89 | $-1.23 | $-1.12 | $-1.34 | — | — | — |
| Operating cash flow | -$71.5M | -$31.1M | -$34.9M | -$46.5M | -$57.5M | -$39.2M | -$52.0M | -$43.3M | -$29.8M | -$29.7M |
| Free cash flow | -$72.5M | -$31.1M | -$34.9M | -$46.5M | -$57.5M | -$39.3M | -$52.1M | -$43.5M | -$30.1M | -$30.4M |
| Cash & equivalents | $213.2M | $34.8M | $41.8M | $47.9M | $90.3M | $137.0M | $158.2M | $209.9M | $123.9M | $40.0M |
| Total assets | $240.3M | $35.6M | $45.3M | $51.8M | $94.3M | $142.8M | $168.0M | $214.8M | $128.6M | $42.4M |
| Total liabilities | $37.3M | $47.1M | $6.9M | $8.9M | $12.7M | $14.6M | $13.8M | $9.4M | $8.9M | $7.1M |
| Shareholders' equity | $203.0M | -$15.5M | $38.4M | $42.9M | $81.6M | $128.2M | $154.2M | $205.5M | $119.7M | $35.3M |
Growth · year-over-year · Revenue CAGR 257.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | — | -86.7% | -93.5% | -88.6% | — | — | — | — | -99.9% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.